Another chapter has been written on the nearly year long effort by Voce Capital management to get Obagi Medical Products (OMPI) sold, when on Monday, 12/3/12, Voce made public another letter sent to the Obagi Board of Directors (BOD) In…
Bullish Archived Articles
XenoPort Catalyst DD – December 31st
Catalyst: XenoPort conducted an End-of-Phase 2 meeting with the FDA in which it received feedback that a proposed development program for XP21279, a novel prodrug of levodopa, could support a potential New Drug Application (NDA) submission under Section 505(b)(2) of…
3 Small Cap Bio-Pharmas With Trade Catalysts And Speculation Investment Potential
Zogenix (ZGNX) engages in the development and commercialization of products for the treatment of central nervous system disorders and pain. Its commercial product includes Sumavel DosePro (sumatriptan injection), a delivery system that offers needle-free subcutaneous administration of sumatriptan for the…
MEI Pharma (MEIP): Significant Catalyst Trade Potential
MEI Pharma, Inc. (MEIP), will be presenting data on Pracinostat, in combination with azacitidine in patients with advanced myelodysplastic syndrome (MDS) at a poster presentation at the American Society of Hematology Annual Meeting on December 10, 2012. An abstract of…
11/30/12 Catalyst Trade And Speculation Investment List
Alexza Pharma (NASDAQ: ALXA) Alexza engages in the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system conditions worldwide. Its product candidates are based on a proprietary technology, the Staccato system, which vaporizes…
Theravance (THRX) reports outcome of the FDA Advisory Committee
Theravance (THRX) reports outcome of the FDA Advisory Committee meeting on VIBATIV (telavancin) for the treatment of nosocomial pneumonia (stock halted) (THRX) 21.40 +0.00 : Co announced the outcome of the Anti-Infective Drugs Advisory Committee (AIDAC) of the FDA meeting…
Huge Swing Trade Potential For Alexza Pharma With Two December Catalysts
Alexza Pharma (NASDAQ: ALXA) engages in the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system conditions. Its product candidates are based on a proprietary technology, the Staccato system, which vaporizes an excipient-free…
BillMyParents, Inc. (BMPI.OB) Due Diligence.
BillMyParents, Inc. (BMPI.OB) Due Diligence. UPDATED 11/27/12: BillMyParents has entered into a spokesman agreement with Justin Bieber, so the rumors I heard from months ago finally turn out to be correct. I expect more news on this tomorrow to supplement…
Near Term Catalysts For Anacor Pharma Should Make For Nice Upside Gain
Trading biophama companies before a catalyst event, if done correctly, can be a very profitable proposition. Some traders and investors who enjoy bringing more risk into play often times will hold through the actual catalyst event. While this does bring…
Upcoming Catalyst Event For Aveo Pharma May Provoke A Short Squeeze
AVEO Pharmaceuticals (AVEO) is dedicated to discovering, developing and commercializing targeted therapies to impact the lives of patients living with cancer. The company has built a pipeline of anti-cancer therapeutics through the use of its proprietary Human Response Platform™. The…
